Parallel analysis of multiple genes on the DNA or RNA level is becoming more and more important, because cancer is identified as a disease that involves multiple genes. To study this cascade of genetic alterations, analysis on a single-gene level cannot be the final answer. Microarray analysis is state-of-the-art technology for fulfilling these scientific needs. The OSUCCC Microarray Shared Resource (MASR) was established as a """"""""developing"""""""" Shared Resource in 1998 initially serving investigators in the Molecular Biology and Cancer Genetics Program with genome wide expression analysis, and subsequently becoming one of the Shared Resources for the entire OSUCCC offering genome wide expression analysis using Affymetrix GeneChips. In September 2002, quantification of RNA integrity by capillary electrophoresis became available, and since September 2003, the MASR has offered validation of microarray results, via an array-based design of primers for real-time PCR. For projects utilizing any of these technologies, the MASR offers multiple services, including experimental design consultation, sample processing, hybridization, scanning, full statistical analysis and consultation, and validation of results. Newer services, such as custom arrays and SNPs are soon to be available. The MASR trains investigators to upload their results to Gene Expression Omnibus (www.ncbi.nlm.nih.gov/geo/) since this becomes mandatory for publication in many journals. The MASR website (www.dnaarrays.org) contains information about services, publications and downloadable protocols and order forms. The MASR offers timely, technical and professional expertise that promotes high quality science at a competitive price. To support OSUCCC researchers, several hundred RNA samples are processed each year for genome wide expression analysis. In addition, several hundred RNA samples are processed for integrity quantification. During 2003, the MASR worked with 30 investigators, 95% of who are CCC members affiliated with four CCC programs, and the amount of MASR service to these members increased 72% over the previous year. There are 42 current or pending grants from OSUCCC members that include utilization of the MASR. The OSUCCC has provided $2.1 M in Institutional support to establish and run the MASR as a """"""""developing"""""""" Shared Resource. We now request CCSG funding that will provide `30% of the total support for this important full Shared Resource over the next five years.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-33
Application #
7630235
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2007-12-01
Budget End
2008-11-30
Support Year
33
Fiscal Year
2008
Total Cost
$228,913
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Lehmann, Vicky; Nahata, Leena; Ferrante, Amanda C et al. (2018) Fertility-Related Perceptions and Impact on Romantic Relationships Among Adult Survivors of Childhood Cancer. J Adolesc Young Adult Oncol 7:409-414
Dix, David B; Seibel, Nita L; Chi, Yueh-Yun et al. (2018) Treatment of Stage IV Favorable Histology Wilms Tumor With Lung Metastases: A Report From the Children's Oncology Group AREN0533 Study. J Clin Oncol 36:1564-1570
Kohnken, Rebecca; Wen, Jing; Mundy-Bosse, Bethany et al. (2018) Diminished microRNA-29b level is associated with BRD4-mediated activation of oncogenes in cutaneous T-cell lymphoma. Blood 131:771-781
Londhe, Priya; Yu, Peter Y; Ijiri, Yuichi et al. (2018) Classical NF-?B Metabolically Reprograms Sarcoma Cells Through Regulation of Hexokinase 2. Front Oncol 8:104
Valenciaga, Anisley; Saji, Motoyasu; Yu, Lianbo et al. (2018) Transcriptional targeting of oncogene addiction in medullary thyroid cancer. JCI Insight 3:
Kiss, Daniel L; Baez, William D; Huebner, Kay et al. (2018) Loss of fragile histidine triad (Fhit) protein expression alters the translation of cancer-associated mRNAs. BMC Res Notes 11:178
Vasu, Sumithira; Kohlschmidt, Jessica; Mrózek, Krzysztof et al. (2018) Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission. Blood Adv 2:1645-1650
Denton, Nicholas L; Chen, Chun-Yu; Hutzen, Brian et al. (2018) Myelolytic Treatments Enhance Oncolytic Herpes Virotherapy in Models of Ewing Sarcoma by Modulating the Immune Microenvironment. Mol Ther Oncolytics 11:62-74
Krasnick, Bradley A; Jin, Linda X; Davidson 4th, Jesse T et al. (2018) Adjuvant therapy is associated with improved survival after curative resection for hilar cholangiocarcinoma: A multi-institution analysis from the U.S. extrahepatic biliary malignancy consortium. J Surg Oncol 117:363-371
Badawi, Mohamed; Kim, Jihye; Dauki, Anees et al. (2018) CD44 positive and sorafenib insensitive hepatocellular carcinomas respond to the ATP-competitive mTOR inhibitor INK128. Oncotarget 9:26032-26045

Showing the most recent 10 out of 2602 publications